Methods for determining responsiveness to an anti-CD47 agent
Methods and kits are provided for determining whether an individual is responsive to an anti-CD47 agent and for determining whether an individual is maintaining responsiveness to an anti-CD47 agent by assaying biological samples for the level of at least one biomarker in a biological sample.
1. A method of determining whether an individual is responsive to an anti-Cluster-of-Differentiation-47 (CD47) agent, the method comprising:
administering the anti-CD47 agent, wherein the anti-CD47 agent is a CD47 blocking antibody, an anti-Signal-Regulatory-Protein-α (SIRPα) antibody, a SIRPα polypeptide that binds to human CD47 and blocks the interaction between CD47 and SIRPα, or a soluble CD47 polypeptide, to the individual after isolating a pre-treatment biological sample, and before isolating a post-treatment biological sample of the same type of biological sample, wherein the biological sample is selected from a blood sample, a serum sample, a plasma sample, a bone marrow sample, a biopsy sample, a fine needle aspirate, a lymph node aspirate, a cystic aspirate, a paracentesis sample, a thoracentesis sample;
assaying the pre-treatment and post-treatment biological samples to determine the level of a positive biomarker Macrophage Inflammatory Protein-1 alpha/Chemokine (C-C) motif ligand 3 (MIP-1α/CCL3); and
determining that the individual is responsive to the anti-CD47 agent when the level of the positive biomarker in the post-treatment biological sample is about 1.5-fold or more greater than the level of the positive biomarker in the pre-treatment biological sample, or determining that the individual is not responsive to the anti-CD47 agent when the level of the positive biomarker in the post-treatment biological sample is less than about 1.5-fold greater than the level of the positive biomarker in the pre-treatment biological sample.
2. The method according to claim 1 , wherein the post-treatment biological sample is isolated in a range from about 1 hour to about 8 days after the anti-CD47 agent is administered to the individual.
3. The method according to claim 1 , wherein the anti-CD47 agent is administered two or more times.
4. The method according to claim 3 , wherein the post-treatment biological sample is isolated about 2 weeks or more after the first administration of the anti-CD47 agent.
5. The method according to claim 1 , wherein the assaying steps comprise measuring the extracellular level of the positive biomarker protein.
6. The method according to claim 1 , further comprising:
providing an analysis indicating whether the individual is determined to be responsive or not responsive to the anti-CD47 agent.
7. The method according to claim 1 , further comprising:
assaying each of the pre-treatment and post-treatment biological samples to determine the level of a neutral biomarker, wherein the neutral biomarker is selected from the group consisting of: Interleukin-12 P70 (IL12P70), Interleukin-1 beta (IL-1β), Interleukin-6 (IL-6), Tumor necrosis factor alpha (TNFα), and a combination thereof.
8. The method according to claim 1 , further comprising:
continuing therapy when the individual is determined to be responsive to the anti-CD47 agent, or altering therapy when the individual is determined to be not responsive to the anti-CD47 agent.
9. A method of determining whether an individual is maintaining responsiveness to an anti-CD47 agent wherein the anti-CD47 agent is a CD47 blocking antibody, an anti-SIRPα antibody, a SIRPα polypeptide that binds to human CD47 and blocks the interaction between CD47 and SIRPα, or a soluble CD47 polypeptide, the method comprising:
assaying a pre-treatment biological sample, a first post-treatment biological sample, and a second post-treatment biological sample of the same type from an individual treated with a first anti-CD47 agent, to determine the level of positive biomarker Macrophage Inflammatory Protein-1 alpha (MIP-1α) (MIP-1α), wherein the biological sample is selected from a blood sample, a serum sample, a plasma sample, a bone marrow sample, a biopsy sample, a fine needle aspirate, a lymph node aspirate, a cystic aspirate, a paracentesis sample, a thoracentesis sample; and
determining that the individual is maintaining responsiveness to the anti-CD47 agent when the level of the positive biomarker in each of the first and second post-treatment biological samples is about 1.5-fold or more greater than the level of the positive biomarker in the pre-treatment biological sample, or determining that the individual is not maintaining responsiveness to the anti-CD47 agent when the level of the positive biomarker in each of the first and second post-treatment biological samples is less than about 1.5-fold greater than the level of the positive biomarker in the pre-treatment biological sample.
10. The method according to claim 9 , wherein a second anti-CD47 agent is administered in a range from about 1 week to about 5 weeks after the first anti-CD47 agent is administered.
11. The method according to claim 10 , wherein the first post-treatment biological sample is isolated in a range from about 1 hour to about 8 days after the first anti-CD47 agent is administered, and wherein the second post-treatment biological sample is isolated in a range from about 1 hour to about 8 days after the second anti-CD47 agent is administered.
12. The method according to claim 9 , wherein the first and second anti-CD47 agents are the same agent.
13. The method according to claim 9 , wherein the second post-treatment biological sample is isolated about 2 weeks or more after the first anti-CD47 agent is administered.
14. The method according to claim 9 , wherein:
(i) the first anti-CD47 agent is administered more than once prior to the isolation of the first post-treatment biological sample;
(ii) the second anti-CD47 agent is administered more than once prior to the isolation of the second post-treatment biological; or
both (i) and (ii).
15. The method according to claim 9 , further comprising assaying the pre-treatment biological sample and the first and second post-treatment biological samples to determine the level of a neutral biomarker, wherein the neutral biomarker is selected from a group consisting of: Interleukin-12 P70 (IL12P70), Interleukin-1 beta (IL-1β), Interleukin-6 (IL-6), Tumor necrosis factor alpha (TNFα), and a combination thereof.
16. The method of claim 1 , wherein the positive biomarker is MIP-1α (CCL3).
17. The method according to claim 1 , wherein the pre-treatment and post-treatment biological samples are a blood sample or a derivative thereof.
18. The method according to claim 1 , wherein the pre-treatment and post-treatment biological samples are a serum sample.
19. The method according to claim 9 , wherein the pre-treatment and post-treatment biological samples are a blood sample or a derivative thereof.
20. The method according to claim 9 , wherein the pre-treatment and post-treatment biological samples are a serum sample.